Skip to main content
OpenTrials
Completed

NCT Number: NCT00388050

Diabetes Medication Choice

The purpose of this study is to examine how different ways of sharing information about diabetes medication treatment options with patients can affect their choices and health.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 2 Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mayo Clinic

Rochester, Minnesota, 55905, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • Have a diagnosis of type 2 diabetes mellitus of any duration; c-peptide test not required
  • Use 1 or 2 oral hypoglycemic agents; not using insulin therapy
  • Are not pregnant
  • Have stable but inadequate glycemic control: both A1C at the time of eligibility and previous A1c within 6 months between 7-9.5%
  • Recognize their primary care provider as their main diabetes care provider
  • Do not have major barriers (i.e., severe hearing impairment, dementia, cannot communicate in English) to participate in shared decision-making (per provider?s assessment)
  • Have no plans to relocate out of town in the next 6 months
  • Enrolment is open to males and females of diverse racial backgrounds

Treatment and study plan

Diabetes Medication Choice decision aid

Behavioral

The decision aid covers five commonly prescribed anti-hyperglycemic medications and their attributes.

Usual Care

Behavioral

Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.

Primary outcomes

  1. Understanding

    Time frame: Directly proceeding the clinical encounter

  2. Decisional Conflict

    Time frame: Directly proceeding the clinical visit

  3. Treatment Action, adherence

    Time frame: Directly proceeding the clinical encounter, 6 months after the clinical encounter

Secondary outcomes

  1. Trust

    Time frame: Directly proceeding the clinical visit

  2. Acceptability

    Time frame: Directly proceeding the clinical encounter

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Collaborators

  • American Diabetes Association

Registry information

Official study title

Wiser Choices for Patients With Type II Diabetes: Diabetes Medication Choice

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
Oct 13, 2006
Registry last updated
Apr 28, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.